
Philip C Mack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9455514/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. Journal of Thoracic Oncology, 2022, 17, 214-227.	1.1	26
2	Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. Oncologist, 2022, 27, 476-486.	3.7	15
3	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <i>EGFR</i> -Mutant NSCLC (SWOG S1403). Clinical Cancer Research, 2022, 28, 3752-3760.	7.0	18
4	A Phase II Study of Telisotuzumab Vedotin in Patients With c–MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). Clinical Lung Cancer, 2021, 22, 170-177.	2.6	41
5	A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer, 2021, 21, 441.	2.6	25
6	Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clinical Lung Cancer, 2021, 22, 541-548.	2.6	8
7	KRAS G12C–Mutant Non–Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2021, 23, 507-520.	2.8	40
8	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	1.1	274
9	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases. Cancer, 2020, 126, 3219-3228.	4.1	106
10	Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab Journal of Clinical Oncology, 2020, 38, 9532-9532.	1.6	7
11	The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clinical Cancer Research, 2018, 24, 3528-3538.	7.0	288
12	Liquid Biopsy for Advanced Non-Small Cell LungÂCancer (NSCLC): A Statement Paper from theÂIASLC. Journal of Thoracic Oncology, 2018, 13, 1248-1268.	1.1	515
13	Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 281-285.	2.6	35
14	Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Cancer Treatment and Research Communications, 2017, 10, 21-26.	1.7	17
15	Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non–Small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 1-4.	2.6	14
16	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 2017, 49, 1693-1704.	21.4	423
17	Papillary Renal Cell Carcinoma: Current Progress and Future Directions. Clinical Genitourinary Cancer, 2014, 12, 74-79.	1.9	16
18	Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non–Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications. Clinical Lung Cancer, 2014, 15, 1-6.	2.6	79

PHILIP C MACK

#	Article	IF	CITATIONS
19	EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 1466-1472.	1.1	65
20	Lower Osteopontin Plasma Levels Are Associated With Superior Outcomes in Advanced Non–Small-Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy: SWOG Study S0003. Journal of Clinical Oncology, 2008, 26, 4771-4776.	1.6	96
21	Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemotherapy and Pharmacology, 2003, 51, 337-348.	2.3	33
22	Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer, 2003, 41, 89-96.	2.0	62
23	IncreasedRB1 abnormalities in human primary prostate cancer following combined androgen blockade. , 1998, 34, 145-151.		29
24	Longitudinal COVID-19 Vaccination–Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer. Journal of Clinical Oncology, 0, , .	1.6	2